{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:28:01Z","timestamp":1787023681427,"version":"build-2736575974"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,4]]},"DOI":"10.18632\/oncotarget.17790","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T08:10:11Z","timestamp":1494490211000},"page":"44232-44241","source":"Crossref","is-referenced-by-count":13,"title":["Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists"],"prefix":"10.18632","volume":"8","author":[{"given":"Loredana","family":"Urso","sequence":"first","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavallari","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Silic-Benussi","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Biasini","sequence":"additional","affiliation":[{"name":"Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zago","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 2, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoracic and Vascular Sciences, University of Padova, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Franco","family":"Conte","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128, Padova, Italy"},{"name":"Medical Oncology Unit 2, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ciminale","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128, Padova, Italy"},{"name":"Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 2, Veneto Institute of Oncology, IRCCS, 35128, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Kindler","year":"2009","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Fraire","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci"},{"key":"6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Levine","year":"2000","journal-title":"Nature"},{"key":"7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.08.019","article-title":"Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment","volume":"97","author":"Pasello","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wahl","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"9","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1038\/onc.2013.410","article-title":"MDM2\u2032s social network","volume":"33","author":"Olivares-Illana","year":"2014","journal-title":"Oncogene"},{"key":"10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-p53 interaction for cancer therapy: are we there yet?","volume":"21","author":"Zhang","year":"2014","journal-title":"Curr Med Chem"},{"key":"11","doi-asserted-by":"publisher","first-page":"e1821","DOI":"10.1038\/cddis.2015.173","article-title":"Targeting Mdmx to treat breast cancers with wild-type p53","volume":"6","author":"Marine","year":"2015","journal-title":"Cell Death Dis"},{"key":"12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/onc.2014.27","article-title":"Mdmx promotes genomic instability independent of p53 and Mdm2","volume":"34","author":"Eischen","year":"2015","journal-title":"Oncogene"},{"key":"13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0014-5793(01)02124-X","article-title":"MDM2 and MDMX can interact differently with ARF and members of the p53 family","volume":"490","author":"Poon","year":"2001","journal-title":"FEBS Lett"},{"key":"14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-14-2300","article-title":"Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia","volume":"21","author":"Kees","year":"2015","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2011.09.040","article-title":"Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells","volume":"314","author":"Shen","year":"2012","journal-title":"Cancer Lett"},{"key":"16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2009.06.002","article-title":"Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells","volume":"287","author":"Kimura","year":"2010","journal-title":"Cancer Lett"},{"key":"17","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1158\/1535-7163.MCT-10-0646","article-title":"Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"18","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-12-2807","article-title":"MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models","volume":"73","author":"Podlaski","year":"2013","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/labinvest.2013.107","article-title":"In vitro and in silico studies of MDM2\/MDMX isoforms predict Nutlin-3A sensitivity in well\/de-differentiated liposarcomas","volume":"93","author":"Maestro","year":"2013","journal-title":"Lab Invest"},{"key":"20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.yexmp.2012.04.001","article-title":"Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients","volume":"93","author":"Gaafar","year":"2012","journal-title":"Exp Mol Pathol"},{"key":"21","doi-asserted-by":"publisher","first-page":"42053","DOI":"10.18632\/oncotarget.5974","article-title":"MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data","volume":"6","author":"Conte","year":"2015","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"Martinez-Lostao","year":"2016","journal-title":"Cell Death Differ"},{"key":"24","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/bjc.2013.636","article-title":"Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL","volume":"109","author":"de Jong","year":"2013","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/CAD.0b013e32835c0311","article-title":"Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation","volume":"24","author":"Kwon","year":"2013","journal-title":"Anticancer Drugs"},{"key":"26","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-12-0487","article-title":"Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells","volume":"72","author":"Pellat-Deceunynck","year":"2012","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","article-title":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","volume":"86","author":"Peikert","year":"2014","journal-title":"Lung Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/138945009789753200","article-title":"Molecular targets in malignant pleural mesothelioma treatment","volume":"10","author":"Favaretto","year":"2009","journal-title":"Curr Drug Targets"},{"key":"29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical Overview of MDM2\/X-Targeted Therapies","volume":"6","author":"Lim","year":"2016","journal-title":"Front Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia","volume":"22","author":"Ruvolo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Higgins","year":"2013","journal-title":"J Med Chem"},{"key":"32","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1158\/1078-0432.CCR-14-0460","article-title":"Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach","volume":"20","author":"Meille","year":"2014","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","article-title":"Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer","volume":"28","author":"Blackhall","year":"2010","journal-title":"J Clin Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1476-4598-6-66","article-title":"Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin","volume":"6","author":"Stahel","year":"2007","journal-title":"Mol Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/JTO.0000000000000198","article-title":"Synergistic antitumor activity of recombinant human Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma","volume":"9","author":"Favaretto","year":"2014","journal-title":"J Thorac Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/cgt.2013.1","article-title":"Gene therapy for malignant mesothelioma: current prospects and challenges","volume":"20","author":"Hiroshima","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1593\/neo.06148","article-title":"p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma","volume":"8","author":"Stahel","year":"2006","journal-title":"Neoplasia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T11:24:32Z","timestamp":1596713072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":37,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2017,7,4]]}},"alternative-id":["17790","28562336"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17790","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]}}}